Form 4 · Filed Jun 26, 2026, 10:45 PM UTC
KRYS/Krystal Biotech, Inc.
Thomas John Charles — EVP, General Counsel
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
3 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 25, 2026 | M | other | 1,000 | $179 | $179,250 | 1,000 |
| Jun 25, 2026 | S | sell | 1,000 | $347 | $347,270 | 0 |
| Jun 25, 2026 | M | other | 1,000 | — | — | 6,500 |
Source: SEC EDGAR raw filing ↗ · Accession 0002114900-26-000009